Nash

Conner Homes Awarded 'Community of the Year' and 'Best Home Design' by The New Home Council

Retrieved on: 
Tuesday, November 23, 2021
Conner, Associate, Four square, Heron, Partnership, White Center, Washington, Theatre Puget Sound, Dutch Colonial Revival architecture, Puget Sound, Nash, Education, Marketing, Olympic Games, Alan McCullough (architect), King County Housing Authority, Farmhouse, Communism in 20 years, Light, Glass, Interior design

Conner Homes was awarded 'Community of the Year,' for its Greenbridge master plan community neighborhoods, which include Materra, Wind Rose and the upcoming Altamura.

Key Points: 
  • Conner Homes was awarded 'Community of the Year,' for its Greenbridge master plan community neighborhoods, which include Materra, Wind Rose and the upcoming Altamura.
  • In partnership with the King County Housing Authority , Conner Homes is the predominant builder of Greenbridge, which was launched as a revitalization effort in the White Center area in Seattle.
  • The second award Conner Homes received was 'Best Home Design Over 3,000 Feet,' which was given to its Heron community in Kirkland.
  • Conner Homes is currently selling homes at 10 communities throughout Seattle, South King County, and the Eastside with pricing starting in the $500's to over $2M.

Michelin Wins Unanimous Defense Verdict In $66 Million Motorcycle Tire Lawsuit In South Carolina

Retrieved on: 
Friday, November 19, 2021
Michelin, North America, View, Paralysis, Maintenance, Multimedia, Nash, Solution, Court of Common Pleas, Company, New York Court of Common Pleas, Restaurant

GREENVILLE, S.C., Nov. 19, 2021 /PRNewswire/ -- A South Carolina jury has ruled unanimously in favor of Michelin North America, Inc., in a high-profile product liability case involving a 2017 motorcycle accident.

Key Points: 
  • GREENVILLE, S.C., Nov. 19, 2021 /PRNewswire/ -- A South Carolina jury has ruled unanimously in favor of Michelin North America, Inc., in a high-profile product liability case involving a 2017 motorcycle accident.
  • Plaintiffs alleged that the motorcycle tire was defectively manufactured.
  • The case is Nash v. Michelin North America, 2019-CP-18-00080, in the Court of Common Pleas, First Judicial Circuit, Dorchester County, South Carolina.
  • Headquartered in Greenville, South Carolina, Michelin North America has approximately 23,000 employees and operates 34 production facilities in the United States and Canada.

The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH

Retrieved on: 
Wednesday, October 20, 2021
Safety, Fibrosis, MPS VI, PPAR, Biology, Research, Diagnosis, MPS, ISIN, IVA, Cirrhosis, NAFLD, Obesity, Patient, Steatosis, Pharmacology, Psoriasis, FDA, Liver cancer, Factor X, Soft tissue injury, Achievement, Non-alcoholic fatty liver disease, Degenerative disease, AbbVie, Adult, Liver disease, Nasdaq, Company, Lists of diseases, Clinical trial, Inflammation, Computational chemistry, Hepatitis, Chronic liver disease, SAF, Pharmacokinetics, NASH, Nash, Liver, Validation, Breakthrough therapy, NAS, Prevalence, Gene expression, Fast track (FDA), Pharmaceutical industry

While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only panPPAR agonist in clinical development.

Key Points: 
  • While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only panPPAR agonist in clinical development.
  • The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH.
  • The NATIVE (NAsh Trial to Validate IVA337 Efficacy) clinical trial was a 24-week randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH.
  • Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH.

Innovative Practices in Student Supportive Services for Adult Education Announced by Manhattan Strategy Group

Retrieved on: 
Tuesday, September 21, 2021
ESOL, Boot camp, Mentorship, FAFSA, Partnership, STEPS, Program, Employment, Catholic (term), El Centro, California, American Sign Language, Transport, Workforce, IET, Speaker, Federal Student Aid, Division, Catholic charities, Office of Career, Technical, and Adult Education, Partnership for Refugees, Topical steroid withdrawal, United States Department of Education, Occupation, Reading, AR, Level 1, Jefferson Community and Technical College, Hearing, Privacy Office of the U.S. Department of Homeland Security, Calhoun Community College, Information technology, Nash Community College, Department, Nash, Technical, AL, College, Industry, Adult education, Medicine, Tutoring

BETHESDA, Md., Sept. 21, 2021 /PRNewswire-PRWeb/ --Manhattan Strategy Group announced today the third round of innovative practices in adult education, as selected by the Advancing Innovation in Adult Education project.

Key Points: 
  • BETHESDA, Md., Sept. 21, 2021 /PRNewswire-PRWeb/ --Manhattan Strategy Group announced today the third round of innovative practices in adult education, as selected by the Advancing Innovation in Adult Education project.
  • Nine practices have been named as innovative for their approaches modeling effective integrated education and training (IET) programs, transitioning adult learners from adult basic education to postsecondary education or training, and increasing access to adult education services.
  • "It is important to shine a light on innovative practices that adult education programs are using to meet the evolving needs of adult learners.
  • "The work of the staff leading these practices reinforces that adult education programs need to consider adult learners' intellectual, social, physical, and emotional needs.

NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, August 5, 2021
Protein-bound paclitaxel, Human, F2, Biology, NGM, Part, Board, Cancer, Drug discovery, Pembrolizumab, Safety, Roger M. Perlmutter, Retina, Lists of diseases, Amgen, Private Securities Litigation Reform Act, AST, Ophthalmology, ESMO, Nash, Oncology, European Society for Medical Oncology, Therapy, Multiple comparisons problem, Cirrhosis, Fibrosis, Leadership, F3, SEC, Injection, Failure, Board of directors, GLOBE, Research, CVM, U.S. Securities and Exchange Commission, Trial of the century, IVT, Patient, COVID-19, Alt, FAF, Geographic atrophy, Risk, Nasdaq, Liver, Pharmaceutical industry, Medical imaging, Cryptocurrency, Fine chemical

NGM anticipates reporting topline data from the CATALINA study in the second half of 2022.

Key Points: 
  • NGM anticipates reporting topline data from the CATALINA study in the second half of 2022.
  • NGM reported a net loss of $36.7million for the quarter ended June30, 2021, compared to a net loss of $25.6 million for the same period in 2020.
  • R&D expenses were $43.6million for the quarter ended June30, 2021, compared to $38.5million for the same period in 2020.
  • General and administrative expenses were $9.8million for the quarter ended June30, 2021, compared to $6.8million for the same period in 2020.

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, August 5, 2021
Chief executive officer, Clinical trial, Association, U.S. Securities and Exchange Commission, Investment, Forward-looking statement, R, Institute of Liver and Biliary Sciences, Master of Business Administration, Liver disease, Private Securities Litigation Reform Act, Drug, European Association for the Study of the Liver, HBsAg, CTA, Viral hepatitis, ASO, HVS, Therapy, Patient, Growth, COVID-19, Degenerative disease, Cam, Data, CHB, Phase 1, HBS, Nash, RNA, Fatty liver disease, Nasdaq, Doctor of Philosophy, Exercise, ILC, Research, Drug development, Terminology, Sirna, Hepatitis, Security (finance), GLOBE, Pharmaceutical industry, Fine chemical

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the second quarter, June 30, 2021.

Key Points: 
  • STOPS and CAM programs: initial data presented at conferences, dosing in 2nd CHB cohorts ongoing
    SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the second quarter, June 30, 2021.
  • At recent scientific conferences, healthy volunteer data from our STOPSprogram and initial antiviral data in CHB subjects from our CAM program, were presented.
  • For both the STOPS and CAM programs, enrollment in the first CHB cohort is complete and is ongoing in the second cohort.
  • Data from additional cohorts are expected to be presented at one or more scientific conferences in the second half of 2021.

Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
Thursday, August 5, 2021
Infectious Diseases, Biotechnology, Pharmaceutical, Health, AbbVie, Association, Research, U.S. Securities and Exchange Commission, Senior, Trial of the century, Retirement, Industry, Patent, Institute of Liver and Biliary Sciences, Incidence, Fatty liver disease, Respiratory syncytial virus, Risk, Hepatitis B virus, Security (finance), European Association for the Study of the Liver, Korea Disease Control and Prevention Agency, Glecaprevir/pibrentasvir, Pharmacokinetics, Virology, Program, Patient, RSVP, COVID-19, Degenerative disease, Severe acute respiratory syndrome coronavirus 2, RSV, Drug discovery, Human, Poster, Nash, Caregiver, Medication, Center, HBV, Income, Marketing, CARES Act, Nasdaq, HCV, Conference, Pharmaceutical industry, Animal, Perfume, Fertilizer

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal third quarter ended June 30, 2021.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal third quarter ended June 30, 2021.
  • Fiscal Third Quarter Ended June 30, 2021 Financial Results
    Total revenue of $21.6 million for the three months ended June 30, 2021 consisted of royalty revenue derived primarily from worldwide net sales of AbbVies hepatitis C virus (HCV) regimen MAVYRET/MAVIRET.
  • This compared to total revenue of $18.7 million for the three months ended June 30, 2020, which also consisted of royalty revenue.
  • Research and development expenses increased to $47.0 million for the three months ended June 30, 2021, compared to $34.7 million for the three months ended June 30, 2020.

Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results

Retrieved on: 
Thursday, August 5, 2021
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Company, Association, Webcast, Facioscapulohumeral muscular dystrophy, Trial of the century, Institute of Liver and Biliary Sciences, Janssen Pharmaceuticals, HSD17B13, Takeda Pharmaceutical Company, Breakthrough therapy, Fibrosis, IND, Congress, European Association for the Study of the Liver, Patient, Hypertriglyceridemia, Alt, RNA interference, Gout, Gene, Clear cell renal cell carcinoma, Phenotype, AAT, Nash, RNA, Arrowhead, Fatty liver disease, Johnson & Johnson, Toxicology, Annual general meeting, Food, Nasdaq, Conference, Pharmaceutical industry, Dietary supplement, Vaccine

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2021.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2021.
  • The company is hosting a conference call today, August 5, 2021, at 4:30 p.m.
  • For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 7398304.
  • Arrowhead also intends to initiate a Phase 2b study and a Phase 3 study of ARO-APOC3 in two additional patient populations in 2021.

CytoDyn Files Lawsuit Against Rosenbaum/Patterson Activist Group for Misleading Shareholders and Waging an Unlawful Proxy Contest

Retrieved on: 
Thursday, August 5, 2021
Infectious Diseases, Biotechnology, AIDS, Health, Optimism, Patent, Severe acute respiratory syndrome, Suite, Social conditioning, Beneficial ownership, Board, Annual general meeting, Clinical trial, District court, Annual report, District, OTC Markets Group, Refusal, HIV, Lavender Hill Mob (gay activist group), Biologics license application, Food and Drug Administration, Nash, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Security (finance), Chief executive officer, Vaccine, THE, Partnership, File, Viral load, SEC, Activism, Form 10-K, Compliance, Food, Company, U.S. Securities and Exchange Commission, United States Patent and Trademark Office, Name, Risk, Patient, Main Street, COVID-19, BLA, CCR5, Forward-looking statement, Animal, Management, Pharmaceutical industry

The suit seeks to enjoin the Activist Group from misleading shareholders and waging an illegal proxy contest to take over control of the Companys Board of Directors (the Board).

Key Points: 
  • The suit seeks to enjoin the Activist Group from misleading shareholders and waging an illegal proxy contest to take over control of the Companys Board of Directors (the Board).
  • The Activist Group has since then stated that it intends to press on with its proxy contest and has continued with its efforts to make misrepresentations to shareholders.
  • We believe the Rosenbaum/Patterson Group has been purposely misleading shareholders and, in the process, has violated securities laws.
  • In its complaint, the Company details a number of misleading statements of the activities of the Rosenbaum/Patterson Group.

Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite Board

Retrieved on: 
Thursday, August 5, 2021
Health, Medical Devices, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Transfer, Company, Chief executive officer, International Life Sciences Institute, Founder, Communications and Information Technology Commission (Saudi Arabia), U.S. Securities and Exchange Commission, United, Industry, Tel Aviv Stock Exchange, Psoriasis, Technology, Hepatocellular carcinoma, Fatty liver disease, Melanoma, Writing, Cuban American National Foundation, Risk, General manager, Bristol Myers Squibb, Digital health, Cancer, Erectile dysfunction, Patient, COVID-19, Hong Kong International Medical Devices and Supplies Fair, The Co Founder, SEC, Liver cancer, Nash, New York Stock Exchange, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Prostate, HCC, Robotics, Drug development, Liver, Colon, Food, Nasdaq, Forward-looking statement, Pharmaceutical industry

During the past 35 years, Mr. Yossi Bornstein has played key roles in the Israeli biomed industry.

Key Points: 
  • During the past 35 years, Mr. Yossi Bornstein has played key roles in the Israeli biomed industry.
  • Mr. Bornstein is the CEO and the founder of Shizim group, a life science holding company.
  • Mr. Bornstein is the founder of ILSI - Israel Life Science Industry Organization and Founder of ITTN - Israel Tech Transfer Organization.
  • We welcome Yossi Borenstein as an External Director and trust that his skills will be highly valuable for Can-Fite, stated Can-Fite CEO Pnina Fishman.